04-NOV-2025 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3799 277 176 104 37 8 02/06/2019 467 187
Screened at PD     1354 120 91 59 24 4      
Pre-Screened prior to PD     2434 146 77 43 13 4      
Treatment-naive     11 11 8 2 0 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     517 24 14 9 4 1      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2011 264 125 74 28 5      
Screened at PD     1123 136 85 57 21 4      
Pre-Screened prior to PD     822 114 32 15 6 1      
Treatment-naive     11 11 8 2 1 0      
After PD on a Lung_MAP Sub-Study     55 3 0 0 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     231 231 109 67 25 5      
S1900G     32 7 2 1 0 0      
S1900J     14 6 3 2 1 0      
S1900K     24 18 11 4 2 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     543 52 40 26 6 2      
Initial sub-study registrations     531 52 40 26 6 2      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 30 30 30 21 5 2 05/22/2025 325 102
Docetaxel plus Ramucirumab Y   16 16 16 12 3 0      
Cemiplimab plus Docetaxel and Ramucirumab Y   14 14 14 9 2 2      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 22 6 2 1 0 0 05/05/2023 295 106
Capmatinib + Osimertinib + Ramucirumab Y   12 5 2 1 0 0      
Capmatinib + Osimertinib Y   10 1 0 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 3 3 1 1 1 0 11/19/2024 218 75
Amivantamab Hyaluronidase Y   3 3 1 1 1 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 14 12 7 3 0 0 08/08/2024 275 91
Tepotinib + Ramucirumab Y   9 8 4 1 0 0      
Tepotinib Y   5 4 3 2 0 0